Oryzon Genomics – ORY (ISIN Code: ES0167733015), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced that the company was granted two unsecured concessional loans from the Ministry of Economy and Competitiveness, Government of Spain, and with the participation of the UE (FEDER funds). The loan was included under the RETOS Collaboration 2015 program. Oryzon will receive approximately 1.3M USD (multiyear disbursements) for further development of its epigenetic inhibitors against neurodegenerative and oncologic indications.

Click here to see the full Press Release

Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Telum Therapeutics Secures €18 Million...

by Telum Therapeutics

Telum Therapeutics, a biotechnology company leveraging proprietary met...

Photos Stream